InMode (INMD) EBT Margin (2018 - 2026)

InMode (INMD) posted EBT Margin of 17.5% for Q1 2026, down 41.92% sequentially from 30.13% in Q4 2025, and down 1136.0% YoY from 1.69% in Q1 2025.

InMode (INMD) EBT Margin (2018 - 2026) Analysis & Trends

InMode has reported EBT Margin for 9 years, with the latest figure at 17.5% in Q1 2026.

Quarterly EBT Margin fell 1136.0% year-over-year to 17.5% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 27.28% (down 836.0% YoY) and the FY2025 annual result came in at 29.78%, down 656.0% from the prior year.
EBT Margin declined to 17.5% in Q1 2026 per INMD's latest filing, from 30.13% in the prior quarter.
Over five years, EBT Margin peaked at 49.94% in Q2 2023 and troughed at 17.5% in Q1 2026.
A 5-year average of 37.33% and a median of 41.19% in 2022 frame the typical range for EBT Margin.
The sharpest annual moves came in 2023 and 2024: EBT Margin soared 742 bps in 2023, then slumped 1870 bps in 2024.
Over 5 years, EBT Margin stood at 47.81% in 2022, then dropped by 1 bps to 47.46% in 2023, then tumbled by 31 bps to 32.92% in 2024, then declined by 8 bps to 30.13% in 2025, then slumped by 42 bps to 17.5% in 2026.
According to Business Quant data, EBT Margin over the past three periods registered 17.5%, 30.13%, and 27.5% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Abbott Laboratories	199.61 Bn	194.01 Bn	7.27 Bn	12.10%
2	Stryker	127.81 Bn	124.34 Bn	4.50 Bn	23.74%
3	Medtronic	119.04 Bn	109.82 Bn	6.41 Bn	18.70%
4	Boston Scientific	73.68 Bn	73.14 Bn	3.85 Bn	19.48%
5	Edwards Lifesciences	51.96 Bn	47.71 Bn	1.35 Bn	29.86%
6	Dexcom	34.36 Bn	32.41 Bn	830.00 Mn	24.27%
7	GE HealthCare Technologies	33.83 Bn	31.72 Bn	2.18 Bn	13.09%
8	Koninklijke Philips	26.36 Bn	23.04 Bn	4.55 Bn	8.91%
9	Steris	23.06 Bn	22.58 Bn	684.20 Mn	18.32%
10	InMode	911.60 Mn	496.43 Mn	71.52 Mn	20.60%

Download Data